nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2007 | Letter to the editor

Reply

verfasst von: T. Vander Borght, S. Asenbaum, P. Bartenstein, C. Halldin, Ö. Kapucu, K. Van Laere, A. Varrone, K. Tatsch

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Talbot JN, Montravers F, Kerrou K, Nataf V, Chevalme Y. FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines. Eur J Nucl Med Mol Imaging 2007; in press. DOI 10.1007/s00259-007-0400-y.

Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006;33:1374–80.CrossRef

Chen W, Delaloye S, Czernin J, Silverman DH, Pope W, Satyamurthy N, et al. Predicting response of malignant brain tumors to bevacizumab and irinotecan therapy with FLT and FDOPA PET. SNM annual meeting 2006, N° 221.

Chen W, Delaloye S, Cloughesy T, Mischel P, Bergsneider M, Satyamurthy N, et al. FDOPA uptake kinetics in human gliomas and the relationship to histopathologic tumor cell proliferation index Ki-67. SNM annual meeting 2006, N° 222.

Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37:1180–2.PubMed

Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [¹⁸F]fluorodopa and [¹¹C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561–7.PubMedCrossRef

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al.¹⁸F-FDOPA PET imaging of brain tumors: comparison study with¹⁸F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904–11.PubMed

Titel: Reply
verfasst von: T. Vander Borght
S. Asenbaum
P. Bartenstein
C. Halldin
Ö. Kapucu
K. Van Laere
A. Varrone
K. Tatsch
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0408-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?

Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study

The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?

FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?